1- cyclopropyl- 3- (3- (5- morpholin- 4- ylmethyl- 1H- benzoimidazol- 2- yl)- 1H- pyrazol- 4- yl)urea

12/01/2013 - "Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers."
12/01/2013 - "NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies."
12/01/2015 - "Dose modeling was performed by analyzing previously published data of AT9283 cancer growth inhibition in vivo. "
01/15/2015 - "AT9283 was well tolerated in children and adolescents with solid tumors with manageable hematologic toxicity. "
06/15/2012 - "AT9283, a pan-aurora inhibitor inhibited growth and survival of multiple solid tumors in vitro and in vivo. "

01/01/2017 - "This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory acute leukemia. "
07/01/2013 - "It was found that AT9283 significantly inhibited the growth and survival of cell lines derived from patients with pediatric leukemia. "
07/01/2013 - "Based on this premise, we evaluated the activity of the Aurora-A/B inhibitor AT9283 against pediatric leukemia cells. "
01/01/2017 - "A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia."
06/01/2014 - "This study sought to identify the maximum tolerated dose (MTD) of AT9283, an inhibitor of Aurora kinases A and B, in patients with relapsed or refractory leukemias. "

12/01/2015 - "The effectiveness of AT9283 was examined in several mouse models engrafted with BCR-ABL(+) leukemic, human multiple myeloma (MM), and human colorectal carcinoma (HCT116) cells. "
01/01/2016 - "A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191."

06/15/2012 - "In this study, we demonstrated that AT9283 had potent activity against Aurora B in a variety of aggressive B-(non-Hodgkin lymphoma) B-NHL cell lines. "
12/01/2013 - "Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. "

06/01/2014 - "A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis."